This is a randomized, double-blind, placebo-controlled study to evaluate the impact of bovine Lactoferrin (bLf) on respiratory tract infections (RTIs) in an elderly population in the United States.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Enrollment
76
Placebo
600 mg
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States
Number of Respiratory Tract Infections
Time frame: 365 days
Severity of Respiratory Tract Infection
Mild, Moderate, or Severe rating
Time frame: 365 days
Duration of Respiratory Tract Infection
Time frame: 365 days
Number of Respiratory Tract Infections
Time frame: 180 days
Treatment of Respiratory Tract Infections
Time frame: 365 days
Complications from Respiratory Tract Infections
Time frame: 365 days
Microorganism causing Respiratory Tract Infection
Time frame: 365 days
Level of protective antibody against influenza virus
Time frame: Baseline, Day 45, Day 90, Day 180, Day 270, and Day 365
Inflammatory cytokine
Time frame: Baseline, Day 45, Day 90, Day 180, Day 270, and Day 365
Protection against apoptosis and oxidative stress
Time frame: Baseline, Day 45, Day 90, Day 180, Day 270, and Day 365
Salivary level of lactoferrin
Time frame: Baseline, Day 45, Day 90, Day 180, Day 270, and Day 365
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Salivary level of thiocyanate
Time frame: Baseline, Day 45, Day 90, Day 180, Day 270, and Day 365
Salivary level of hypohalous acid
Time frame: Baseline, Day 45, Day 90, Day 180, Day 270, and Day 365
Complete Blood Count
Time frame: Baseline, Day 45, Day 90, Day 180, and Day 365
Comprehensive Metabolic Panel
Time frame: Baseline, Day 45, Day 90, Day 180, and Day 365
Body Weight
Time frame: Baseline, Day 45, Day 90, Day 180, and Day 365
Short Form (12) Health Survey Version 2 (SF-12v2®)
Time frame: Baseline, Day 45, Day 90, Day 180, and Day 365
Use of medical treatments
Time frame: 365 days
Medically confirmed Adverse Events
Time frame: 365 days
COVID Vaccine specific inflammatory panel
IGG concentrations and geometric means of SARS psuedovirus neutralization titers and Cytokines
Time frame: Day 45, Day 90, Day 180, Day 270, and Day 365
Influenza Hemagglutination-inhibition Antibody Titer
Time frame: Pre-booster, Post-booster day 2, Post-booster day 7, and Post-booster day 28
Cytokine Panel
Time frame: Pre-booster, Post-booster day 2, Post-booster day 7, and Post-booster day 28